[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-570857-105":59,"doc-detail-570857-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prescription-drugs-oxycontin-abuse-and-diversion-and-efforts-to-address-the-problem-highlights-of-gao-04-110","Prescription Drugs - OxyContin Abuse and Diversion and Efforts to Address the Problem - Highlights of GAO-04-110","","Highlights of GAO-04-110 examine OxyContin abuse and diversion in the United States after the FDA approval of Purdue Pharma’s controlled-release pain reliever. The study reviews OxyContin’s marketing and promotion, factors linked to misuse, and actions taken by federal, state, and company entities. Findings describe aggressive promotion to a broader range of conditions, weaknesses related to labeling and availability, and initiatives including stronger safety warnings and risk-management guidance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prescription-drugs-oxycontin-abuse-and-diversion-and-efforts-to-address-the-problem-highlights-of-gao-04-110/570857/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prescription-drugs-oxycontin-abuse-and-diversion-and-efforts-to-address-the-problem-highlights-of-gao-04-110/570857.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-17","2026-10-13",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why did GAO study OxyContin abuse and diversion?","Question",{"text":112,"@type":113},"GAO was asked to examine concerns that OxyContin was being abused and diverted for illicit use, after reports surfaced in early 2000.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What marketing and promotion factors were linked to abuse and diversion?",{"text":117,"@type":113},"The report describes Purdue’s extensive marketing using an expanded sales force that encouraged prescribing not only for cancer pain but also for noncancer pain, with FDA and DEA raising concerns about advertising and promotional compliance.",{"name":119,"@type":110,"acceptedAnswer":120},"What actions were taken to address OxyContin abuse and diversion?",{"text":121,"@type":113},"Federal and state agencies and Purdue implemented actions including stronger safety warnings, collaboration on a risk-management plan, DEA’s national action plan, investigations by state agencies, and Purdue’s educational programs and disciplinary measures.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},570857,1792295370,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":39,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","# Prescription Drugs:OxyContin Abuseand Diversion andEfforts to Addressthe Problem\n\nUnited States Government AccountabilityOffice  \nSCHOLAR'SCHOICE  \nPrescription Drugs:OxyContin Abuse andDiversion and Efforts to Address the Problem  \nUnited States Government Accountability Office  \nThis work has been selected by scholars as being culturally important,and is part ofthe knowledge base of civilization as we know it.This work was reproduced fromthe original artifact,and remains as true to the original work as possible.Therefore,you will see the original copyright references,library stamps(as most of theseworks have been housed in our most important libraries around the world),andother notations in the work.  \nThis work is in the public domain in the United States of America,and possibly othernations.Within the United States,you may freely copy and distribute this work,asno entity(individual or corporate)has a copyright on the body of the work.  \nAs a reproduction of a historical artifact,this work may contain missing or blurredpages,poor pictures,errant marks,etc.Scholars believe,and we concur,that thiswork is important enough to be preserved,reproduced,and made generallyavailable to the public.We appreciate your support of the preservation process,andthank you for being an important part of keeping this knowledge alive and relevant.  \nDecember 2003  \n# PRESCRIPTIONDRUGS\n\nOxyContin Abuse andDiversion and Effortsto Address theProblem  \nHighlights of GAO-04-110,a report tocongressional requesters  \n## Why GAO Did This Study\n\nAmid heightened awareness thatmany patients with cancer andother chronic diseases suffer fromundertreated pain,the Food andDrug Administration(FDA)approved Purdue Pharma'scontrolled-release pain relieverOxyContin in 1995.Sales grewrapidly,and by 2001 OxyContin hadbecome the most prescribed brand-name narcotic medication fortreating moderate-to-severe pain.In early 2000,reports began tosurface about abuse and diversionfor illicit use of OxyContin,whichcontains the opioid oxycodone.GAO was asked to examineconcerns about these issues.Specifically,GAO reviewed(1)howOxyContin was marketed andpromoted,(2)what factorscontributed to the abuse anddiversion of OxyContin,and  \n(3)what actions have been taken toaddress OxyContin abuse anddiversion.  \n## What GAO Recommends\n\nTo improve efforts to prevent oridentify abuse and diversion ofcontrolled substances such asOxyContin,FDA's risk  \nmanagement plan guidance shouldencourage pharmaceuticalmanufacturers with new drugapplications to submit plans thatcontain a strategy for identifyingpotential problems with abuse anddiversion.FDA concurred withGAO's recommendation.DEAagreed that such risk managementplans are important,and Purduestated that the report appeared tobe fair and balanced.  \nwww.gao.gov/cgi-bin/getrpt?GAO-04-110.  \nTo view the ful product,including the scopeand methodology,click on the link above.For more information,contact Marcia Crosseat(202)512-7119.  \n# PRESCRIPTION DRUGS\n\nOxyContin Abuse and Diversion andEfforts to Address the Problem  \n## What GAO Found\n\nPurdue conducted an extensive campaign to market and promote OxyContinusing an expanded sales force to encourage physicians,including primarycare specialists,to prescribe OxyContin not only for cancer pain but also asan initial opioid treatment for moderate-to-severe noncancer pain.OxyContin prescriptions,particularly those for noncancer pain,grewrapidly,and by 2003 nearly half of all OxyContin prescribers were primarycare physicians.The Drug Enforcement Administration (DEA)hasexpressed concern that Purdue's aggressive marketing of OxyContin focusedon promoting the drug to treat a wide range of conditions to physicians whomay not have been adequately trained in pain management.FDA has takentwo actions against Purdue for OxyContin advertising violations.Further,Purdue did not submit an OxyContin promotional video for FDA reviewupon its initial use in 1998,as required by FDA regulations.  \nSeveral factors may","cbCaiijdtO9dwaVP","https://ap.wps.com/l/cbCaiijdtO9dwaVP","pdf",4234792,72,"English","# Why GAO Did This Study\n# What GAO Recommends\n# What GAO Found","[{\"question\":\"Why did GAO study OxyContin abuse and diversion?\",\"answer\":\"GAO was asked to examine concerns that OxyContin was being abused and diverted for illicit use, after reports surfaced in early 2000.\"},{\"question\":\"What marketing and promotion factors were linked to abuse and diversion?\",\"answer\":\"The report describes Purdue’s extensive marketing using an expanded sales force that encouraged prescribing not only for cancer pain but also for noncancer pain, with FDA and DEA raising concerns about advertising and promotional compliance.\"},{\"question\":\"What actions were taken to address OxyContin abuse and diversion?\",\"answer\":\"Federal and state agencies and Purdue implemented actions including stronger safety warnings, collaboration on a risk-management plan, DEA’s national action plan, investigations by state agencies, and Purdue’s educational programs and disciplinary measures.\"}]","Prescription Drugs - OxyContin Abuse and Diversion and Efforts to Address the Problem - Highlights of GAO-04-110 | PDF",1791883432,181,[147,151,155,159,163,167,171,175],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-18/f62174befd3c314b00de28cb0928211e.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-18/86da69b7a798bcc93f48f19ded5858ad.webp",982,1318,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-18/232a852f53c18598b2a9311f08dd5f86.webp",981,1317,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-18/7981e078545c527342a030bdafb93838.webp",980,1315,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-18/cd6225f705884fe3ee4bb3e48e29b572.webp",979,1314,{"page_no":29,"url":168,"width":169,"height":170},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-18/359cc91b3a6ec262de1d85a1de784777.webp",978,1296,{"page_no":34,"url":172,"width":173,"height":174},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-18/6758a0c49b6036a8dc51d026e9190ba5.webp",977,1295,{"page_no":39,"url":176,"width":177,"height":178},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-18/a9317aa1fb5f0b7a5ad5dc40cfffdaef.webp",976,1294]